These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 20493453)
1. [Chemotherapy with docetaxel in prostate cancer. A case report]. Lechevallier E; Culine S; Benchikh El Fegoun A Prog Urol; 2010 Mar; 20 Suppl 1():S80-3. PubMed ID: 20493453 [TBL] [Abstract][Full Text] [Related]
2. [Prostate cancer: future strategies for chemotherapy management]. Fizazi K Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S77-9. PubMed ID: 18297905 [TBL] [Abstract][Full Text] [Related]
3. [Docetaxel for metastatic prostate cancer: early is better]. Gietema JA; Oosting SF Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569 [TBL] [Abstract][Full Text] [Related]
4. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. Sonpavde G; Sternberg CN Int J Urol; 2010 Mar; 17(3):228-40. PubMed ID: 20088874 [TBL] [Abstract][Full Text] [Related]
7. [Strategy in advanced castration-resistant prostate cancer]. Gross-Goupil M; Roca S; Pasticier G; Ravaud A Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582 [TBL] [Abstract][Full Text] [Related]
8. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002. DeGrendele H Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878 [No Abstract] [Full Text] [Related]
9. The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer. Gupta K; Elkon J; El-Bahesh E; Aragon-Ching JB Anticancer Agents Med Chem; 2016; 16(9):1166-71. PubMed ID: 24359499 [TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518 [TBL] [Abstract][Full Text] [Related]
11. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574 [TBL] [Abstract][Full Text] [Related]
12. Management of metastatic castration-resistant prostate cancer after first-line docetaxel. Harrington JA; Jones RJ Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937 [TBL] [Abstract][Full Text] [Related]
13. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854 [TBL] [Abstract][Full Text] [Related]
14. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005 [TBL] [Abstract][Full Text] [Related]